A new vaccine for HIV has shown promising results, according to research published in The Lancet Journal.
The research states that four vaccines were administered to 393 healthy adults for 48 weeks and created immune responses against HIV. At the same time, a parallel study was conducted on Rhesus monkeys where they were given the combination of vaccines to test resistance against a virus similar to HIV, called simian-human immunodeficiency virus.
The vaccine will now be tested on 2,600 women in southern Africa who are at risk of contracting HIV.
"These results represent an important milestone.This study demonstrates that the Ad26 prime, Ad26 plus gp140 mosaic stimulates the candidate HIV vaccine induced robust immune responses in humans and monkeys with magnitude, kinetics, phenotype and durability and also provided 67% protection against viral challenge in monkeys, "said Dan Barouch, director of the Virology and Vaccine Research Center at Beth Israel Deaconess Medical Center, at ContagionLive.
However, Barouch added that these results should be interpreted with caution and that the verdict on this vaccine should be given after the second phase of the trials.
This is one of five HIV vaccines will be tested in humans in a span of 35 years. According to WHO data, approximately 36.7 million people were living with HIV in 2016 and almost 1.8 million people were affected in the same year.